Results 91 to 100 of about 136,011 (340)

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO [PDF]

, 2018
Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from first-line doublets plus a targeted agent.
Allegrini, G, Antoniotti, C, Bergamo, F, Boni, L, Buonadonna, A, Cortesi, E, Cremolini, C, Falcone, A, Fontanini, G, Granetto, C, Lonardi, S, Loupakis, F, Marmorino, F, Masi, G, Moretto, R, Racca, P, Ronzoni, M, Sensi, E, Tomasello, G, Tonini, G, Zagonel, V, Zaniboni, A   +21 more
core   +3 more sources

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

New England Journal of Medicine, 2011
BACKGROUND Vascular endothelial growth factor is a key promoter of angiogenesis and disease progression in epithelial ovarian cancer. Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in
R. Burger, M. Brady, M. Bookman, G. Fleming, B. Monk, Helen Q. Huang, R. Mannel, H. Homesley, J. Fowler, B. Greer, M. Boente, M. Birrer, S. Liang   +12 more
semanticscholar   +1 more source

The Role of Bevacizumab in Glioblastoma [PDF]

Journal of the National Comprehensive Cancer Network, 2014
Glioblastoma (GBM) is the deadliest and most aggressive of the primary brain malignancies. Outcomes for patients remain poor, with the course of the disease often associated with significant neurologic morbidity because of tumor location within the central nervous system (CNS).
openaire   +3 more sources

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

Molecular Oncology, EarlyView.
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen, Cara Ellen Wogsland, Emmet McCormack, Johanna Mäenpää, Kristine Madsen, Karen Stampe Petersson, Mansoor Raza Mirza, Line Bjørge   +11 more
wiley   +1 more source

Efficacy and Safety of Bevacizumab Biosimilar (Encoda) Compared With Reference Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer: A Multicenter, Real-World Study

Clinical Medicine Insights: Oncology
Background: The bevacizumab biosimilar (Encoda), which was approved by the National Medical Products Administration (NMPA) in China in 2019, is a biosimilar of bevacizumab.
Han Shan, Mengmeng Wang, Shuohan Huang, Hongyue Liu, Jiyong Liu, Qiong Du   +5 more
doaj   +1 more source

A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma

Clinical Medicine Insights: Oncology, 2008
Background Bevacizumab and irinotecan may represent one of the most active treatments in progressive malignant glioma. Limited published experience with bevacizumab in patients with CNS tumors raises concerns regarding toxicity, particularly in regards ...
Tina Mayer, Jill Lacy, Joachim Baehring M.D.   +2 more
doaj   +1 more source

CENTRAL MACULAR THICKNESS AFTER COMBINED THERAPY OF BEVACIZUMAB INTRAVITREAL INJECTION AND TOPICAL DICLOFENAC COMPARED WITH BEVACIZUMAB INTRAVITREAL INJECTION ALONE IN DIABETIC MACULAR EDEMA

IJRETINA (International Journal of Retina), 2021
Introduction: To evaluate whether the combination of diclofenac eye drops and bevacizumab intravitreal injection would provide additional benefits over bevacizumab alone in the treatment of naïve diabetic macular edema (DME).
Melvina Nidya Sandra, Yumni Shabrina, Tri Wahyu Widayanti, Retno Ekantini, Agus Supartoto, Muhammad Bayu Sasongko, Supanji Haryanto   +6 more
doaj   +1 more source

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer. Efficacy in combination with hormonal therapy [PDF]

, 2012
Background: Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no ...
Cognetti F., D'Auria G., De Vita F., Fabi A., Ferretti G., Giannarelli D., Metro G., Nistico C., Papaldo P., Russillo M., Vidiri A.   +10 more
core   +3 more sources

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review

Frontiers in Oncology
In clinical use, bevacizumab has improved the overall survival (OS) and progression-free survival (PFS) of malignant solid tumors, and the safe use of bevacizumab has gradually become the mainstream direction of clinical, nursing and pharmaceutical ...
Ke Chen, Boyang Jiang, Boyang Jiang, Huiping Yan, Huiping Yan, Liu Yang, Liu Yang, Zheling Chen, Zheling Chen   +8 more
doaj   +1 more source